Aviceda Announces 3 Presentations about AVD-104, its Lead Glyco-mimetic Nanoparticle, As a Novel Tre
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Aviceda Therapeutics, a private biotech company focused on developing the next generation immuno-modulators by harnessing the power of glycobiology to modulate the innate immune system and alleviate chronic, non-resolving inflammation, today announced their upcoming oral and poster...
Source: pharmiweb.com